在危急病患者中预防胃肠道出血的药理预防
Adrian Wong1, Sandra L Kane-Gill2,3, Jeffrey F Barletta4
1Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Current opinion in critical care
|February 24, 2025
概括
压力预防 (SUP) 可以减少上部胃肠道出血 (UGIB),但不能改善死亡率. 谨慎的特定患者处方和未来的AI使用是优化SUP和预防UGIB的关键.
科学领域:
- 关键护理医学 关键护理医学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 上部胃肠道出血 (UGIB) 发生率仍然很高,尽管急性护理的进展.
- 压力预防 (SUP) 是减少重症患者UGIB的关键疗法.
- 最近的出版物提供了对SUP处方的最新建议.
研究的目的:
- 审查和评论压力预防 (SUP) 的最新建议.
- 确定UGIB预防和SUP的未来研究领域.
- 讨论影响适当使用SUP的患者特定因素.
主要方法:
- 对最近关于压力预防 (SUP) 的重要手稿的审查.
- 对 SUP 处方的最新建议进行分析.
- 关于SUP有效性和安全性的证据的评论.
主要成果:
- SUP降低了UGIB的发生,但没有显示死亡率的好处.
- 质子抑制剂 (PPI) 可能与重症患者的死亡率增加有关.
- 短期使用 SUP 具有最小的不良事件;长期使用会增加风险.
结论:
- 根据最近的数据,针对患者的具体考虑对于优化SUP至关重要.
- 需要进一步的研究来完善SUP指南.
- 人工智能可以帮助识别有风险的患者,为适当的SUP处方和UGIB减少提供帮助.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
34
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
34
Peptic Ulcer Disease IV: Management
60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
327
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
327
Prevention of Further Absorption of Poison
777
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
777
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
350
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
350
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
362
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
362


